slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 230,431-230,460
Pages 10,126
Rows per page 30
Component
230,431-230,460 of 303,780
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
06
The slide uses a timeline framework to connect high-level goals with specific 2024 milestones.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
The slide uses a split layout with a left panel for advisors/board and a right panel for the leadership team and a footer metric.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
12
Slide 12 of the deck.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProductLoop · Mece Breakdown1 hit
13
The slide uses a timeline-based customer journey framework to map clinical progression against therapeutic limitations.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Loop · Mece Breakdown1 hit
14
The slide uses a matrix-like structure to compare drug generations against clinical outcomes.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Loop · Mece Breakdown1 hit
15
The slide uses a split-screen layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed clinical trial enrollment metrics by dose cohort and patient population.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
The slide presents two side-by-side tables detailing patient characteristics and treatment history for the ALKOVE-1 study cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Data cut-off: 8 Aug 2023. Includes detailed breakdown of resistance mutations and prior treatment history.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Clinical trial data (ALKOVE-1) showing efficacy of NVL-655 across different patient cohorts.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
22
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
23
Data cut-off: 8 Aug 2023. N=93 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide outlines a multi-cohort study design with specific patient populations and trial objectives.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
The slide uses a sidebar 'AT A GLANCE' to summarize key drug development parameters.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
27
The slide uses a timeline-based framework to contrast current treatment options with clinical unmet needs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses three distinct chart types to demonstrate competitive advantages in potency, PK, and selectivity.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide presents a clinical trial snapshot including patient eligibility criteria and a breakdown of patient enrollment by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide presents two side-by-side tables detailing patient characteristics and treatment history for a clinical trial cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
Includes a summary table of best responses and a waterfall plot showing percentage change in target lesions by dose cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
33
Includes clinical trial data from ARROS-1 Phase 1 study.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
The chart shows pharmacokinetic curves for four different dose levels against four target efficacy thresholds.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
Includes three distinct preclinical assay results: In Vitro Activity, Selectivity Index, and Brain Penetrance.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
40
The slide highlights the 'OnTarget 2026' initiative, which serves as a strategic milestone for product approval.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
05
The slide uses a table-like structure to represent a clinical trial roadmap, incorporating regulatory designations and partner logos.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 25 slidesNuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit